替加环素血药浓度监测与不良反应的关联性分析
Correlation analysis between tigecycline therapeutic concentration monitoring and adverse reactions
目的: 建立人血浆中替加环素的高效液相色谱-串联质谱(HPLC-MS/MS)测定方法,用于研究患者体内的药代动力学特征,并探讨其血药浓度与药物诱导性肝损伤及凝血功能障碍的相关性。方法: 采用蛋白沉淀法处理血浆,以 Eclipse Plus C18 柱分离,0.1% 甲酸水-甲醇梯度洗脱,利血平为内标,流速 0.3 mL/min,正离子模式检测并考察方法各项性能。随后,收集 2024 年 6 月至 2025 年 6 月期间使用替加环素患者的临床资料与血浆样本(n=72)。根据是否发生不良反应(ADR)分组,比较两组血药浓度差异,采用受试者工作特征曲线(ROC)分析确定 ADR 发生的血药浓度折点,并计算敏感度、特异度及曲线下面积(AUC)。结果: 所建方法线性范围为 50~5 000 ng/mL,精密度、准确度及稳定性值均小于 10%,满足临床检测要求。通过 ROC 曲线得到替加环素导致肝损伤的折点为 515.34 ng/mL,致凝血功能障碍的折点为 243.59 ng/mL。结论: 成功建立人血浆中替加环素的 HPLC-MS/MS 方法,替加环素的血药浓度与导致肝损伤及凝血功能障碍有关,建议临床上应联合血药浓度与肝功能、凝血指标监测以守护用药安全。
AIM: To establish a high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method for the determination of tigecycline in human plasma, which was used to study the pharmacokinetic profile in patients and to investigate the correlation between its blood concentration and drug-induced hepatic injury and coagulation dysfunction. METHODS: Plasma was processed by protein precipitation, separated on an Eclipse Plus C18 column, eluted by a 0.1% formic acid water-methanol gradient, with Reserpine as an internal standard, at a flow rate of 0.3 mL/min and detected in the positive ion mode and examined the method properties. Subsequently, clinical data with plasma samples were collected from patients using tigecycline between June 2024 and June 2025 (n=72). The groups were grouped according to whether or not an adverse reaction (ADR) occurred, the differences in blood concentrations between the two groups were compared, and the blood concentration breakpoints at which ADRs occurred were determined using subject's work characterization curve (ROC) analysis, and the sensitivity, specificity, and area under the curve (AUC) were calculated. RESULTS: The linear range of the proposed method was 50-5 000 ng/mL, and the precision, accuracy and stability values were less than 10%, which met the requirements of clinical testing. The ROC curve showed that the fold point of tigecycline causing liver injury was 515.34 ng/mL, and that of coagulation dysfunction was 243.59 ng/mL. CONCLUSION: The HPLC-MS/MS of tigecycline in human plasma was successfully established, and the tigecycline blood concentration is related to the cause of liver injury and coagulation dysfunction. It is recommended that blood concentration monitoring combined with liver function and coagulation indicators should be applied clinically to ensure medication safety.
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
福建省自然科学基金(2024J011468)
莆田学院院校联合基金重点项目(2024107)
/
| 〈 |
|
〉 |